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Abstract
Background: PiT1 (or SLC20a1) encodes a widely expressed plasma membrane protein functioning as a high-affinity Na+-
phosphate (Pi) cotransporter. As such, PiT1 is often considered as a ubiquitous supplier of Pi for cellular needs regardless of
the lack of experimental data. Although the importance of PiT1 in mineralizing processes have been demonstrated in vitro
in osteoblasts, chondrocytes and vascular smooth muscle cells, in vivo evidence is missing.
Methodology/Principal Findings: To determine the in vivo function of PiT1, we generated an allelic series of PiT1 mutations
in mice by combination of wild-type, hypomorphic and null PiT1 alleles expressing from 100% to 0% of PiT1. In this report
we show that complete deletion of PiT1 results in embryonic lethality at E12.5. PiT1-deficient embryos display severely
hypoplastic fetal livers and subsequent reduced hematopoiesis resulting in embryonic death from anemia. We show that
the anemia is not due to placental, yolk sac or vascular defects and that hematopoietic progenitors have no cell-
autonomous defects in proliferation and differentiation. In contrast, mutant fetal livers display decreased proliferation and
massive apoptosis. Animals carrying two copies of hypomorphic PiT1 alleles (resulting in 15% PiT1 expression comparing to
wild-type animals) survive at birth but are growth-retarded and anemic. The combination of both hypomorphic and null
alleles in heterozygous compounds results in late embryonic lethality (E14.5–E16.5) with phenotypic features intermediate
between null and hypomorphic mice. In the three mouse lines generated we could not evidence defects in early skeleton
formation.
Conclusion/Significance: This work is the first to illustrate a specific in vivo role for PiT1 by uncovering it as being a critical
gene for normal developmental liver growth.
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Introduction
PiT1 is a membrane protein originally identified as the human
retrovirus receptor for GALV (Gibbon Ape Leukemia Virus), and
was therefore designated GLVR1 [1]. Based on the observation that
GLVR1 possesses sequence similarity to pho-4+, a phosphate (Pi)
permease of Neurospora crassa, several groups have demonstrated that
GLVR1 is a high affinity Na+-dependent Pi transporter, which was
consequently renamed PiT1 [2,3,4]. PiT1 belongs to the Pi
transporter (PiT) family comprising conserved symporters through-
out all kingdoms that use either sodium or proton gradients to
transport Pi [5]. In mammals, the PiT family is assigned to the solute
carrier series SLC20 which also includes PiT2, initially identified
as the amphotropic murine retrovirus receptor Ram-1 [6] and
subsequently characterized as a Pi transporter with transport
characteristics very close to PiT1 [2,4]. The broad tissue distribution
of PiT1 and PiT2 has led to the proposal that these transporters
could play a housekeeping role for cellular Pi homeostasis [2,7,8].
Although plausible, direct experimental data is lacking. Moreover,
significant differences between PiT1 and PiT2 expression levels and
ratios are observed among tissues [9], which suggests that these two
transporters may have specific and non redundant roles in vivo.
Due to the requirement of large amounts of Pi in bone
physiology, the regulation of PiT1 has been well documented in
bone and cartilage in vitro models. In osteoblast-like cells, PiT1, but
not PiT2, mRNA expression and Na+-Pi cotransport are regulated
by various factors such as Pi [10], epinephrine [11], insulin-like
growth factor 1 (IGF-1) [12,13] and bone morphogenic protein 2
(BMP2) [14]. Importantly, PiT1, but not PiT2 is upregulated
during osteoblast differentiation, consistent with a dedicated role
of PiT1 in this process [15]. Expression and activity of PiT1 in
chondrogenic cells was found to be regulated by extracellular Pi
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concentration [16] and transforming growth factor-b (TGF-b)
[17]. Moreover, vascular calcification occurring in pathological
situations such as hyperphosphatemia-induced calcifications of
blood vessels and osteoarthritis, shares a number of similarities
with osteogenesis and bone mineralization [18]. Recent in vitro
studies have suggested that PiT1 may be implicated in patholog-
ical vascular calcification [19]. Particularly, inhibition of Pi uptake
by PiT1 small hairpin RNA in cultured vascular smooth muscle
cells (VSMCs) blocked the expression of Pi-induced osteogenic
differentiation markers, Runx2 and osteopontin, indicating that
PiT1 might be a major mechanism for controlling vascular
calcification and VSMC phenotypic state [18,19].
However, it should be noted that the above-mentioned studies
have been conducted in in vitromodels and it is not clear which role
PiT1 plays in normal bone or vascular physiology. Particularly, the
discrete expression of PiT1 in a subset of hypertrophic chondro-
cytes late in development [20], its weak expression in osteoblasts
and VSMCs [21] together with its low transport capacity [22]
make it an unlikely candidate to face the tremendous Pi needs for
bone or vascular calcification. Moreover, since most studies aimed
at elucidating PiT1 regulation and function were conducted in
tissues in which Pi per se plays an important role (i.e. mineralized
tissues), very little information is available for other tissues. Since
PiT1 is expressed in numerous non-mineralizing tissues, it is
entirely possible that PiT1 possesses regulated tissue-specific roles
going beyond a housekeeping Na+-Pi transport function. In line
with this hypothesis, we have recently identified a new function for
PiT1, which is independent of its Na+-Pi cotransport activity and is
critical for cell proliferation [9]. These recent data show for the
first time that PiT1, in addition to its retrovirus receptor and Na+-
Pi cotransporter functions, modulates cell proliferation in vitro. The
physiological relevance of this third function is unknown, and
further illustrates the need for a wider and more physiological
approach to decipher the role of PiT1 in vivo.
To provide insights into the physiological role of PiT1 in mice,
we established an allelic series of PiT1 mutations arising from the
combination of normal, hypomorphic and null PiT1 alleles in
mice. The new mutant mouse lines described here were used to
address the following questions: i) is PiT1 essential for embryo
development? ii) are PiT1 and PiT2 physiological roles redundant?
iii) is PiT1 essential to skeletal or vessel formation during mouse
development? iv) are the growth, development or function of
specific organs impaired in the absence of PiT1? In what follows,
we provide answers to these questions and report as a key finding
that PiT1 deficiency causes mid-gestation embryonic lethality due
to an impaired liver development leading to profound anemia.
Methods
Animals and Ethics Statement
All mouse models used in the study were on a 129sv/J 6
C57BL6/J mixed background. Animal care and maintenance
were provided through the University Paris Descartes accredited
Animal Facility at Necker Faculty of Medicine (Paris). Mice were
maintained on rodent laboratory chow (Special Diet Services,
Witham, Essex, UK) containing 0.73% calcium, 0.52% phosphate
and 600 IU/kg of vitamin D3. All procedures were approved by
the Animal Care and Use Committee of the University Paris
Descartes.
Derivation of PiT1 Genetically Modified Mice
A BAC clone (RP23-160G19) containing the genomic sequence
of mouse PiT1 was purchased (Invitrogen). Using a recombineer-
ing approach [23], we constructed a targeting vector containing
PiT1 59- and 39-homologous arms (4115 bp and 3645 bp,
respectively), a neomycin resistance (neo) cassette flanked by frt
sites in intron 5, and a 59 and 39 loxP sites 532 bp upstream and
934 bp downstream from exon 5, respectively. The final vector
containing a diphtheria toxin cassette (MC1-DTA) permitting
negative selection was verified by sequencing. 129/Sv ES cells
were electroporated with 20 mg of linearized targeting vector and
selected under G418 treatment. EcoRV digested genomic DNA
from 336 ES clones was screened by Southern blotting using a
PiT1 59 external probe. Nine positive clones were further analyzed
using 59 and 39 probes after digestion of the DNA with two other
restriction enzymes, and four clones with the predicted homolo-
gous integration were identified. ES cells were injected into
C57BL/6 blastocysts, chimaeric males bred to C57BL/6 females
and germ-line transmission of the mutation determined by
Southern blot analysis and PCR amplification of tail DNA.
Heterozygous offspring (PiT1neo/+ mice) were bred either to
ACTB:FLPe mice [24] to remove the neo cassette, leading to
PiT1lox/+ animals, or to PGK-Cre mice [25] to produce PiT1D5/+
mice. Genotyping of neonates and embryos was performed by
PCR from tail or yolk sac DNA. Primers used for recombineering,
probe amplification and genotyping are listed in Table S1.
Gene Expression
Total RNA was isolated from cells and tissue using NucleoSpin
RNA columns (Macherey Nagel). Northern analysis of total RNA
(25 mg) and RT-PCR amplification were performed as described
previously [26]. Specific primers are listed in Table S1. Real-time
PCR was performed using SYBR green chemistry (Thermo
Scientific) on an ABI Prism 7700 detection system. The glucuron-
idase or pinin genes were used as reference genes and expression
differences were calculated as described previously [27]. In situ
hybridization was performed as described [28]. PiT1 probes (Table
S1) were transcribed with SP6 or T7 promoters with the DIG RNA
labeling kit (Roche Applied Science). Color reaction was performed
by using BM purple and sections were counterstained with
hematoxilin.
Hematopoietic Progenitor Cell Assays
Single-cell suspensions from E12.5 fetal livers were plated in
1 ml 1% methylcellulose in Iscove’s modified Dulbecco’s medium
supplemented with 30% FCS, 1% crystallized BSA, and 100 mM
2-mercaptoethanol in the presence of 2 U/ml EPO, 10 ng/ml IL-
3, 20 ng/ml thrombopoietin and 100 ng/ml stem cell factor.
Samples were plated in duplicate 35-mm bacterial Petri dishes and
incubated at 37uC in a humidified incubator containing 5% CO2.
Colonies were scored at day 2 for CFU-E, day 7 for CFU-
granulocyte-macrophage (CFU-GM) and mature burst-forming
unit-erythroid (BFU-E), and days 10 to 12 for CFU-granulocyte,
erythroid, monocyte, megakaryocyte (CFU-GEMM).
Immunohistochemistry and Apoptosis Analysis
Embryos were fixed overnight in 4% buffered formalin. Four-
micron sections were produced from paraffin embedded samples
and immunohistochemistry was performed according to anti-
body specification. PECAM-1 (CD-31) was detected in embryos,
placental or yolk sac sections using a rat purified anti-CD31
antibody (1/100, clone a-MEC 13.3; BD Pharmigen), as described
[29]. Proliferating cells were detected with the anti-Ki67 antibody
(AbCys). To perform BrDU labeling, pregnant mice were injected
intra-peritoneally with 0.3 ml of 50 mg/ml BrDU (Sigma) in PBS.
Embryos were harvested after 1 h and fixed overnight in 4%
buffered formalin. After embedding in paraffin, detection of
BrdU was performed with anti-BrDU antibody (BD Biosciences).
PiT1 and Liver Development
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To reveal apoptotic cells, DeadEndTM Colorimetric TUNEL
System (Promega) and immunohistochemistry using anti-activated
caspase 3 (Asp175; Cell Signalling) were used according to the
manufacter’s instructions.
Partial Hepatectomy
Eight- to twelve-week-old wild-type mice were subjected to
sham operation or two-thirds partial hepatectomy between 9 AM
and 12 PM, under general anesthesia with inhaled isoflurane
(n = 4 for each genotype and time point). Animals were killed at
different times after surgery. Sham animals were operated without
any liver resection. Livers were snap frozen into liquid nitrogen for
mRNA preparations. All experiments were approved by the
institutional committee and were in accordance with European
guidelines for the care and use of laboratory animals.
Embryonic Fibroblasts Culture and Analysis
Isolation of MEFs was performed using established procedures
and cultured in DMEM supplemented with 10% FBS in 5%CO2
and a humidified atmosphere. For growth curves, 20,000 MEFs
were seeded in triplicates in 24-well plates. Every day, cells were
trypsinized and counted. Pi transport was measured as previously
described [30]. Apparent affinity constant (Km) and maximal
transport rate (Vmax) were calculated by nonlinear curve fitting,
assuming Michaelis-Menten kinetics.
Immunoblot Analysis
Cells were lysed for 30 min in ice-cold lysis buffer (150 mM
NaCl, 10 mM Tris HCl, 5 mM EDTA, 1% NP40, 0.1% SDS,
0.5% deoxycholate, 1 mM Na3VO4, 1 mM NaF, 5 mM Na
pyrophosphate, 0.2 M PMSF and a protease inhibitor cocktail
from Roche), and the protein extract was boiled and transferred to
PVDF membranes. After blocking with 5% milk/TBST, blots
were probed with anti-AMPKs, anti-phospho-AMPKs (Thr172)
antibodies (Cell Signaling Technology) and secondary antibody
according to the manufacter’s instructions.
Fatty Acid, Phospholipids and Cholesterol Analysis
The lipid-containing organic phase was obtained from erythro-
cyte suspensions by liquid-liquid extraction with 6 volumes of
chloroform/methanol (2:1, v/v), centrifuged at 800 g for 3 min,
and the resulting lower phase was aspirated. Cholesterol and
phospholipid content were monitored by thin layer chromatogra-
phy. For cholesterol analysis, aliquots of 4 ml of the different extracts
and cholesterol standard were applied to HP-K plates (Whatman,
Clifton, NJ), developed in chloroform/acetone (95:5 v/v), stained
with the CuSO4 reagent, and developed by charring at 170uC. For
phospholipid analysis, two sequential mobile phases were utilized as
follows: chloroform/triethylamine/ethanol/water (30:30:34:8) and
hexane/diethyl ether (100:4.5). The resulting bands were analyzed
by the Imagemaster software (Amersham Biosciences). For fatty
acid analysis, a 30 ml aliquot of a 1 mg/ml solution of heptade-
canoate (17:0, Sigma Chemical, St Louis, MO) in chloroform-
methanol (1:1, vol/vol) was added to extracts as an internal
standard. Organic extracts were evaporated to dryness under a
nitrogen stream and transmethylated with boron trifluoride and
methanolic base reagent (BF3-methanol) (Supelco) as previously
described [31]. Briefly, dry extracts were resuspended in 0.5 ml of
methanolic base, vortexed, and incubated at 100uC for 3 min,
followed by addition of 14% BF3 in methanol (0.5 ml), vortexing,
incubation at 100uC for 1 min, addition of hexane (0.5 ml),
vortexing, incubation at 100uC for 1 min, and addition of 6.5 ml
of saturated NaCl. Samples were vortexed and centrifuged at 800 g
for 2 min. The hexane upper layer was transferred to a fresh glass
tube. Methyl esters of fatty acids were injected into a Hewlett-
Packard 5890A gas chromatograph with a flame ionization
detector. A 30 m Supelcowax column (Supelco) (0.5 mm internal
diameter) was used. The oven temperature was 150uC for 2 min,
increased to 200uC for 5 min, held at 200uC for 4 min, increased to
240uC for 8 min, and after 3 min increased to 260uC and held at
this temperature until the end of the program. The detector
temperature was 300uC. Fatty acid methyl ester peaks were
identified by comparison of retention times with a standard mixture
of fatty acid methyl esters (Supelco) and quantified by comparison
with the internal standard detector response.
Cartilage and Bone Staining
For staining and visualization of whole skeletons, fetuses or mice
were dissected and stained with alizarin red S or alcian blue 8GX
(Sigma), or both, as described previously [32].
Results
Generation of a PiT1 Mutant Allelic Series
To determine the in vivo function of PiT1, we targeted the PiT1
locus by homologous recombination in ES cells and generated an
allelic series of mutations ranging from mild impairment to
elimination of PiT1 function. We inserted loxP sites 59 and 39 to
PiT1 exon 5 and a neomycin resistance (neo) cassette flanked by frt
sites in intron 5 (Fig. 1A). Cre-mediated deletion of exon 5 is
expected to produce a frame shift of the remaining sequence and
convert the floxed PiT1 allele to a null allele. Correctly targeted ES
cells were identified by Southern blot analysis (Fig. 1B and C),
chimeric mutant mice derived and PiT1neo/+ heterozygous mice
obtained (Fig. 1D).
PiT1neo/neo mice resulting from PiT1neo/+ intercrosses were born
at a lower than expected Mendelian frequency (Table S2). Analysis
of PiT1neo transcripts demonstrated an aberrant splicing due to the
presence of cryptic splice sites resulting in a hybrid mRNA
containing an additional portion of PiT1 intron 5 and the coding
sequence of neo (Fig. S1A and B). Translation of the PiT1neo
transcript would produce a non-functional PiT1 protein lacking
exons 6 to 11 due to the presence of an in frame stop codon 65
bases downstream to exon 5. Accordingly, wild-type PiT1 mRNA
levels are significantly reduced both in PiT1neo/+ and PiT1neo/neo
E11.5 embryo (35% and 15% of the wild-type, respectively)
(Fig. 1F). These results indicate that PiT1neo is a hypomorphic
allele, leading to a reduction in the amount of functional PiT1 gene
expression, most probably accounting for the non-Mendelian
frequency of PiT1neo/neo pups (Table S2). To excise the neo cassette
PiT1neo/+ animals were crossed to ACTB:FLPe mice [24], leading
to PiT1lox/+ offspring. A Mendelian distribution was observed in
progeny obtained from PiT1lox/+ intercrosses and no phenotypic
difference was observed among genotypes, demonstrating that the
PiT1lox allele is functionally equivalent to the wild-type allele.
Accordingly, the level of wild-type PiT1 mRNA was found normal
in both PiT1lox/+ and PiT1lox/lox mice (Fig. 1F).
To generate PiT1-null animals, PiT1neo/+ mice were crossed
with the PGK-Cre deleter strain mice [25]. The deletion was
confirmed by Southern blot, PCR and northern blot analysis
(Fig. 1C to E). PiT1D5/+ mice appeared indistinguishable from
PiT1+/+ littermates, were viable and fertile producing offspring in
normal Mendelian ratios when crossed with wild-type animals
(Table 1). However, no PiT1D5/D5 offspring were found among
208 newborn pups from heterozygote intercrosses, indicating that
PiT1 disruption results in embryonic lethality (Table 1).
PiT1 and Liver Development
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Similarly, PiT1neo/D5 compound heterozygotes resulting from
PiT1neo/+ and PiT1D5/+ matings were not viable (Table S3). Wild-
type PiT1 mRNA levels in E12.5 PiT1neo/D5 embryos represented
6% of normal levels whereas PiT2 expression was increased, as
was seen in PiT1neo/neo and PiT1D5/D5 mice (Fig. 1F). Hence,
together with the PiT1+/+, PiT1neo/+, PiT1D5/+, PiT1neo/neo and
PiT1D5/D5, these mice contribute to the establishment of an allelic
series of mutant mice in which PiT1 is expressed from 100% to 0%
(Fig. 1F).
Mid-Gestation Lethality Due to Defective Liver
Development and Anemia in PiT1D5/D5 Embryos
To identify at which developmental stage PiT1-null embryos
die, genotyping of litters harvested from serial timed matings from
E3.5 to birth was performed (Table 1). Results revealed that living
PiT1D5/D5 embryos were detected up to E12.5, and that no
PiT1D5/D5 embryos survived after this stage. Until E9.5 no
macroscopic abnormalities were observed in PiT1D5/D5 embryos
by gross anatomical and histological examinations. At E10.5,
embryos were found to be slightly growth retarded, without
morphological abnormalities (Fig. 2A). At E12.5, PiT1D5/D5
embryos could be easily recognized by their significant growth
retardation and profound anemia (Fig. 2B). The most striking
defect was observed in the developing liver, occupying only a small
fraction of the abdominal areas (Fig. 2C and D). Morphological
examination showed that E12.5 mutant livers, composed of four
lobes, were extremely pale and severely reduced in size as
compared to normal livers (Fig. 2E). Total liver nucleated cell
counts represented only 2% of wild-type livers at this stage
(Fig. 2F). Real-time RT-PCR analysis of RNA extracted from
E12.5 PiT1+/+ and PiT1D5/D5 embryos demonstrated that the level
of albumin and a-fetoprotein transcripts in mutant embryos was
markedly reduced, further suggesting the decrease in hepatoblast
number or function (Fig. 2G). Histological analysis of PiT1D5/D5
E12.5 livers further confirmed the reduced cellularity and
increased empty space, indicating less dense packing of cells in
the PiT1D5/D5 as compared to the wild-type livers (Fig. 2H and I).
Hypocellularity and presence of large sinuses in the mutant livers
were already visible at E11.5 (Fig. 2J and K).
Absence of Placental, Yolk Sac and Vascular Defects in
PiT1D5/D5 Embryos
We next evaluated whether defects in placenta, yolk sac or
vasculature could be responsible of the observed anemia seen in
PiT1D5/D5 embryos. Wild-type and mutant placentas appeared
similar, except that mutant placentas were paler (Fig. S2A). The
chorionic plate and labyrinthine trophoblast layer were well
developed in PiT1D5/D5 placentas, and no differences in
vascularization were evidenced on histological sections (Fig. S2B
to E). In addition, we did not detect differences in placental cell
proliferation and apoptotic signals between mutant and control
placentas (Fig. S2F to I). This suggests that the observed anemia is
highly unlikely to be caused by defects in placental development
and subsequent failure to establish the maternal-fetal interface for
oxygen and nutrient exchange.
No hemorrhage was found in the mutant embryos, suggesting
that a default in the vasculature is unlikely to be responsible for the
anemia. At E11.5 the tree-like architecture of the vasculature was
clearly visible (Fig. 3A and B), although severe decrease in red blood
cells number impedes from visualizing the entire network. Close
examination of E12.5 mutant yolk sac revealed a highly developed
vasculature devoid of red blood cells (Fig. 3C to E). Histological
examination and anti-PECAM-1 staining of endothelial cell of
Figure 1. Generation of an allelic series of mutations at the PiT1
locus. (A) Schematic representation of PiT1 alleles and targeting vector
representing intronic DNA (horizontal lines), PiT1 exons (black boxes) a neo
cassette flanked by frt sites (unfilled box) and a diphtheria toxin cassette
(hatched box). Heterozygous PiT1neo/+ mice were produced as described.
Flp-mediated recombination at frt sites generates the PiT1lox allele, whereas
Cre-mediated recombination at loxP sites (open triangles) generates the
PiT1D5 allele. The positions of restriction sites used for Southern blot
screening are shown: E, EcoRV; N, NheI; A, ApaLI. (B) Southern blot analysis of
EcoRV-digested DNA from G418-resistant ES cell clones. The wild-type
fragment is 33 kb in size, whereas correct recombination generates a
15.4 kb fragment using a 59 probe and a 17.3 kb fragment using a 39 probe
(bar). A correctly targeted clone is represented (#18). (C) Genotype analysis
of mice heterozygous for the various PiT1 alleles. Southern blots were
performed on ApaLI or NheI-digested kidney DNA isolated from mice as
indicated, using 59 and 39 probes. (D) PCR genotyping of mice from tail
genomic DNA. Primer positions (triangles) are indicated in (A) and their
sequences are reported in Table S1. (E) Northern blot of E12.5 whole embryo
total RNA as indicated, probed with 32P-labeled PiT1 coding region cDNA. (F)
Real-time RT-PCR analysis of the expression of the wild-type PiT1 and PiT2
alleles in E11.5 embryos from the PiT1 allelicmutant series, as indicated. Note
that PiT2 is overexpressed in situation when the expression PiT1 becomes
very low. * and # indicate significant differences as compared to wild-type
controls with P,0.05 and P,0.001, respectively (Student’s t test).
doi:10.1371/journal.pone.0009148.g001
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PiT1D5/D5 yolk sac sections confirmed that major defects in the
vasculature were absent from PiT1D5/D5 mutants (Fig. 3F to I).
Similarly, no difference in endothelial cell staining could be seen
between wild-type and mutant sections throughout the entire
embryo (data not shown). Anti-PECAM-1 staining on liver serial
sections showed that although vessels appeared more numerous on
the mutant livers, this was largely due to the severely reduced size of
the liver (Fig. 3J and K). While these data do not exclude the
possible existence of minor defects, they indicate that there were no
major vascular defects shortly before the occurrence of embryonic
death at E12.5.
PiT1D5/D5 Embryos Have Elevated Proportion of
Circulating Primitive Erythrocytes and Identical Number
of Hematopoietic Progenitors in the Liver
Peripheral blood smears showed that the majority of erythroid
cells in PiT1D5/D5 mutants were larger than in the wild-type
(Fig. 4A and B), which was confirmed by measuring the cell and
nucleus mean diameters of erythroid cells in the PiT1+/+ and
PiT1D5/D5 mice (Fig. 4C). Since primitive erythroid precursors are
approximately twice as large and contain twice as much
hemoglobin than their mature counterparts [33], this suggests
that PiT1D5/D5 embryos have a higher proportion of immature
erythroid cells. We confirmed this by quantifying the expression
of hemoglobin genes (Fig. 4D). Hemoglobin molecules contain
globin chains derived both from the a-globin (Hbb-a) and b-globin
(Hbb-b) gene loci. Although definitive erythroid cells in the mouse
express a1-globin, a2-globin, b1-globin, and b2-globin, primitive
erythroid cells in addition express f-globin (Hba-x), bH1-globin
(Hbb-bh1), and ey-globin (Hbb-y) [33,34]. We found that the
amount of adult and fetal forms of globin chains in the mutant
represented 2 to 9% and 19 to 25% of the wild-type, respectively.
Accordingly, the ratios between fetal and adult forms of
hemoglobin was higher in E12.5 PiT1D5/D5 livers than in the
wild-type (Fig. 4D), suggesting that the maturational globin
switching may be impaired or delayed in PiT1-deficient embryos.
Alternatively, a defect in the developmental niche provided by the
fetal liver for the maturation and enucleation of primitive
erythrocytes may explain this phenotype [35].
We conducted in vitro progenitor assays to characterize whether
the erythropoietic defect in PiT1D5/D5 embryos could result from
either an intrinsic defect in hematopoietic progenitors or a failure
in the ability of the fetal-liver microenvironment to support
erythropoiesis. Single cell suspensions cultured in methylcellulose
showed that the absolute number of CFU-E, BFU-E, CFU-GM
and CFU-GEMM colonies per PiT1D5/D5 fetal liver were reduced
48-, 90-, 74- and 46-fold, respectively, as compared with values in
wild-type littermates (Fig. 4E to H). However, when results were
expressed as number of colonies per 105 nucleated fetal-liver cells,
no significant difference was found between normal and mutant
livers suggesting that a similar fraction of PiT1D5/D5 and wild-type
fetal livers are composed of hematopoietic cell progenitors (Fig. 4E
to H). The ratio of BFU-Es to CFU-Es was similar in PiT1+/+ and
PiT1D5/D5 embryos, suggesting that there was no defect in the
terminal differentiation of erythroid progenitors. Both the size of
CFU-E, BFU-E, CFU-GM and CFU-GEMM colonies and the
number of cells per colony were similar (836694 and
766658 cells/colony for PiT1+/+ and PiT1D5/D5, respectively).
These results suggest that although PiT1D5/D5 fetal livers were
severely hypoplastic, some hematopoietic stem cells do migrate
there and have the potential to give rise to all erythropoietic
lineages. Because the PiT1D5/D5 hematopoietic committed pro-
genitor cells were able to proliferate and differentiate normally
when tested in vitro, this suggests that the anemia seen in E12.5
PiT1D5/D5 embryos is unlikely to arise from a hematopoietic cell-
autonomous defect.
Increased Apoptosis and Reduced Growth Rate in
PiT1D5/D5 Livers
We next asked whether the reduction in liver cell density was
caused by reduced proliferation or whether a loss of liver cells had
occurred due to cell death. Histological sections revealed that most
of the E12.5 mutant livers displayed abundant fragmented
pyknotic nuclei, whereas only few were visible on control sections
(Fig. 5A and B). TUNEL staining of liver sections confirmed the
above observation (Fig. 5C to F). Of interest, the level of TUNEL
staining in E11.5 mutant livers was comparable to that of wild-
type controls (Fig. 5E and F). Immunodetection of activated
caspase 3, revealed a significant number of apoptotic cells in E12.5
PiT1D5/D5 livers, while few apoptotic cells were found in control
livers (Fig. 5G and H). The level of activated caspase 3 in E11.5
mutant livers was comparable to that of wild-type (Fig. 5I and J).
Table 1. Genotypes of the progeny obtained from heterozygous PiTD5/+ mice intercrosses.
Stage Litters (n) Embryos (n) PiT1+/+ a PiT1D5/+ PiT1D5/D5 (alive)b PiT1D5/D5 (dead)
E3.5 3 27 7 (26%) 13 (48%) 7 (26%) 0
E9.5 3 26 7 (27%) 13 (50%) 6 (23%) 0
E10.5 6 52 13 (25%) 24 (46%) 15 (29%) 0
E11.5 15 127 34 (27%) 61 (48%) 32 (25%) 0
E12.5 19 162 41 (25%) 79 (49%) 37 (23%) 5 (3%)
E13.5 10 79 22 (28%) 43 (54%) 0** 14 (18%)
E14.5 4 38 11 (29%) 22 (58%) 0* 5 (13%)
E15.5 4 35 11 (31%) 24 (69%) 0* 0
Birth (P1) 25 208 60 (29%) 148 (71%) 0** 0
Total 89 754 206 427 97 24
aAbsolute number and frequency (%).
bSurviving embryos were defined as those with beating hearts. No surviving PiT1D5/D5 embryos were found alive past E12.5 stage.
*, ** significant differences between observed frequency of living PiT1D5/D5 and expected frequency of 25%, according to Mendelian distribution of the genotypes with
P,0.01 and P,0.001, respectively. Significance of distribution was calculated using x2 test.
doi:10.1371/journal.pone.0009148.t001
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Figure 2. Disruption of the PiT1 gene leads to defective liver
development and anemia. (A–B) Comparison between wild-type and
PiT1D5/D5 embryos at E10.5 (A) and E12.5 (B). Note the reduced size, pale
appearance and small liver (black arrow) of the E12.5 mutant embryos. (C,
D) Haematoxilin and eosin (H&E) staining of E12.5 sections from PiT1+/+
(C) and PiT1D5/D5 embryos (D). fl: fetal liver; mg: mid-gut loop; h: heart. Bar,
100 mm. (E) Morphological appearance of wild-type and mutant E12.5
fetal livers. Bar, 0.5 mm (F) Fetal liver nucleated cell counts in E12.5 wild-
type and mutant embryos. (G) Quantification of PiT1, PiT2, albumin and
a-fetoprotein mRNA expression by real-time RT-PCR in E12.5 PiT1+/+ and
PiT1D5/D5 embryos. (H–K) H&E staining of E12.5 (H,I) and E11.5 (J,K) sagital
sections of PiT1+/+ and PiT1D5/D5 livers illustrating the hypocellularity of
the mutant livers. Bar, 100 mm. # indicate significant differences as
compared to wild-type controls with P,0.001 (Student’s t test).
doi:10.1371/journal.pone.0009148.g002
Figure 3. Absence of major vascular defects in PiT1D5/D5 mice.
(A–B) Yolk sac membranes from wild-type and PiT1D5/D5 E11.5 embryos
illustrate the tree-like architecture of the vasculature (white arrow).
Despite that mutant yolk sac appears white, vessels are present but often
devoid of red blood cells (black arrow). (C) Gross appearance of wild-type
(left) and PiT1D5/D5 (right) E12.5 embryos with intact yolk sac membranes.
(D–E) Close examination of wild-type and mutant yolk sac shows empty
vessels in themutant yolk sac (F–G) H&E staining of yolk sac cross-sections
from wild-type and PiT1D5/D5 E12.5 embryos illustrate that, although null
yolk sacs present with many vessels (black arrow), they are almost devoid
of red blood cells (white arrow). (H–I) Anti-PECAM-1 IHC (+Ab) of PiT1+/+
and PiT1D5/D5 yolk sac cross-sections at E12.5 illustrating the presence of
endothelial cells in both genotypes (black arrow). A negative control
(2Ab) is shown to illustrate the specificity of the signal. (J–K) Anti-PECAM-
1 IHC (+Ab) of PiT1+/+ and PiT1D5/D5 liver cross-sections at E12.5 illustrating
the presence of endothelial cells in both genotypes. A negative control
(2Ab) is shown to illustrate the specificity of the signal. Bar, 100 mm.
doi:10.1371/journal.pone.0009148.g003
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We next examined the proliferation status of PiT1-deficient livers.
Staining with the proliferation marker Ki67 was less intense in
sections of E12.5 PiT1D5/D5 livers than in the wild-type (Fig. 5K
and L). These results were confirmed by performing BrDU pulse-
labeling of dividing cells in E11.5 pregnant females, and
subsequent detection of BrDU-positive cells. Wild-type fetal livers
showed heavy nuclear staining in the entire liver, whereas BrDU
Figure 4. Elevated proportion of circulating primitive erythro-
cytes and identical number of hematopoietic progenitors per
fetal liver in PiT1D5/D5 embryos. (A, B) May-Gru¨nwald/Giemsa
staining of blood smears from E12.5 embryos. At E12.5 almost all
blood cells are nucleated; enlarged cells represent primitive erythroid
precursors. (C) Mean cell and nucleus diameter of erythroid cells in
PiT1+/+ and PiT1D5/D5 E12.5 embryos, measured with the NIS-Elements
AR 3.00 software. (D) RT-PCR analysis of the expression of globin chains
in E12.5 PiT1+/+ and PiT1D5/D5 livers. Results are expressed as ratios
between fetal and adult globin expression, as indicated. (E–H) In vitro
differentiation of E12.5 fetal-liver cells from wild-type and PiT1D5/D5
embryos. The number of CFU-E (E), BFU-E (F), CFU-GM (G), and CFU-
GEMM (H) colonies per fetal liver (FL) or per 105 nucleated fetal-liver
cells are indicated. * and # indicate significant differences as compared
to wild-type controls with P,0.05 and P,0.001, respectively (Student’s
t test).
doi:10.1371/journal.pone.0009148.g004
Figure 5. Apoptotic and proliferation defect in PiT1-deficient
fetal livers. (A–B) H&E staining of E12.5 livers illustrating the presence
of large sinuses in mutants. Higher magnification views (boxes)
illustrate the abundance of pyknotic nuclei (arrow) in the mutant liver.
(C–D) TUNEL analysis on sections from the same fetal livers shown in
(A–B). Note the significant number of positively stained cells (green) in
the PiT1D5/D5 livers. Nuclei were stained with DAPI (blue). (E–F) TUNEL
analysis on E11.5 fetal liver sections revealed that apoptotic signals
were similar in wild-type and mutant livers. (G–J) Activated caspase 3
staining of E12.5 (G,H) and E11.5 (I,J), mutant liver sections. White
arrows indicate examples of positively stained cells. (K–L) Ki67 staining
shows that while overall cell density is reduced, proliferation is reduced
but ongoing in mutant embryos (arrow). (M–N) Pulse BrDU labeling of
E11.5 embryos. Positively labeled cells (arrow) are less numerous in the
mutant. Bar, 100 mm.
doi:10.1371/journal.pone.0009148.g005
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staining was reduced in PiT1-null samples directly demonstrating a
subnormal growth rate in this organ (Fig. 5M and N). Antibodies
recognizing the fetal hepatocyte marker cytokeratin 18 (CK18)
revealed label-positive cells in PiT1 mutant embryos at E12.5,
suggesting that, at least at this stage, developing hepatocytes were
present (Fig. 6A and B). However, it was notable that CK18
staining revealed disorganized tissue architecture and that marker-
positive cells were often rounded up or pyknotic. Staining against
the erythroid cell marker Ter119 revealed a significant reduction
in marker-positive cells in mutant livers (Fig. 6C and D),
correlating with the loss of erythroid lineage cells. Activated
caspase 3 staining of sections from the same livers revealed that
Ter119-positive cells were not labeled in mutant sections whereas
apoptosis was evident in CK18-expressing cells (Fig. 6E and F).
Thus, while developing hepatocytes emerge in PiT1 mutant livers
at E12.5, loss of hepatocytes by apoptosis is a frequent occurrence
whereas the scarcity of Ter119-labeled cells in mutant livers is
unlikely to correlate with apoptotic activity.
PiT1 Expression in the Liver
Although widespread, PiT1 expression in adult mouse, rat and
human is rather variable between tissues and is low in the adult
liver [2,7,8]. Our in situ hybridization (ISH) experiments on E12.5
wild-type embryo sections demonstrated that PiT1 was expressed
at low levels throughout the embryo, except in the liver. Faint PiT1
expression was detected in the developing brain as previously
described [8], but this signal was much lower than the high level of
expression found in the fetal liver (Fig. 7A and B). This result is in
sharp contrast with the low level of expression of PiT1 in adult
livers, but is consistent with a role of PiT1 during developmental
liver growth. We confirmed these results by quantifying the
expression of PiT1 and PiT2 in fetal E12.5 and post-natal P15
wild-type livers by real-time RT-PCR. The level of PiT1 in the
fetal liver was 4.4-fold higher than that in the post-natal liver,
whereas fetal and post-natal PiT2 expression were similar (Fig. 7C).
Moreover, quantification of the relative expression of PiT1 and
PiT2 in wild-type fetal and post-natal livers revealed that PiT1
expression was 3.4-fold higher in fetal livers and 1.7-fold lower in
post natal livers than PiT2 (Fig. 7D), further illustrating the need
for PiT1 during developmental liver growth. Of importance, while
PiT1 was undetectable in PiT1D5/D5 E12.5 livers, the expression of
PiT2 was 1.5-fold higher than in the wild-type livers (Fig. 7E), a
value that is comparable to the increase found in the whole mutant
Figure 6. Apoptotic defects in PiT1 mutant fetal liver cells. (A–B)
Cytokeratin 18 (CK18) staining (brown) reveals the presence of
hepatoblasts in E12.5 mutant sections (black arrows). (C–D) Staining
of Ter119 (brown) reveals great loss of erythroid cells in E12.5 mutant
liver sections (black arrows). (E–F) Activated caspase 3 staining of E12.5
liver sections reveals excessive apoptotic activity in mutant liver
sections (black arrow) that was not present in Ter119 positive cells
(white arrows). Bar, 100 mm.
doi:10.1371/journal.pone.0009148.g006
Figure 7. PiT1 expression during liver growth. (A) In situ
hybridization (ISH) of a wild-type E12.5 embryo shows heavy PiT1
signal in the developing liver (black arrow), whereas low signal is
detected in the brain (white arrows) and throughout the embryos. (B)
ISH with the PiT1 sense probe gives no signal. Bar, 1 mm. (C) Ratios of
PiT1 and PiT2 mRNA expression levels between embryonic (E12.5) and
post-natal (P15) wild-type livers, as determined by real-time RT-PCR. (D)
PiT1/PiT2 expression ratios in embryonic (E12.5) and post-natal (P15)
livers, as determined by real-time RT-PCR. (E) Quantification of the
expression of PiT1 and PiT2 in normal and PiT1D5/D5 E12.5 livers by real-
time RT-PCR. Note the 1.5-fold overexpression of PiT2 in PiT1-null livers.
(F) Gene induction after partial hepatectomy. Total cellular RNA
collected in a time course after partial hepatectomy in wild-type mice
was analyzed by real time RT-PCR for the expression of PiT1, PiT2 and
PCNA as a marker of proliferation. Results are reported after
normalization to the expression of Pinin.
doi:10.1371/journal.pone.0009148.g007
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embryo (Fig. 1F). To determine in which cell types PiT1 was most
expressed, we performed immunostaining of PiT1 on wild-type
and mutant sections using PiT1 antibodies from commercial or
laboratory sources [9]. Unfortunately, we are unable to generate a
specific signal using the available anti-mouse antibodies, and the
expression of PiT1 in specific liver cell types during mouse
development remains an open question. However, PiT1 has been
localized in adult hepatocytes, but not in cholangiocytes, in rat
livers [36]. Consistent with this finding, we further illustrated the
role of PiT1 in liver growth by performing partial hepatectomy on
normal adult mice. In this model, the remnant liver undergoes
rapid division to re-establish the original weight of the organ. Our
results show that, although PiT2 expression is unchanged, PiT1 is
highly (3.5-fold) induced within 2 h following partial hepatectomy
(Fig. 7F) indicating that PiT1 is likely to be essential during the
early stage of compensatory liver growth. Although further
experiments are necessary, this observation could be consistent
with a higher expression of PiT1 in developing versus adult fetal
livers and the low proliferation rate of PiT1D5/D5 livers.
Proliferation of PiT1D5/D5 Primary MEFs, but Not Na+-Pi
Transport, Is Severely Impaired
As genetic inactivation of PiT1 resulted in embryonic lethality,
together with decreased cell proliferation, we evaluated whether
the absence of PiT1 could also affect MEFs proliferation in vitro.
Results show that PiT1D5/D5 MEFs proliferated very slowly,
displaying a mean doubling time of 38 h, a 2.1-fold increase
compared with the doubling time of 18 h observed for PiT1+/+
MEFs (Fig. 8A). PiT1D5/+ MEFs had an intermediate growth rate
(mean doubling time of 20 h). As the main reported function of
PiT1 is to couple inward Pi uptake to the Na+ gradient across the
cell plasma membrane, we characterized the Na+-dependent Pi
uptake in PiT1-deficient MEFs. Interestingly, our results showed
that Na+-Pi uptake in PiT1-null MEFs was unaffected (Fig. 8B),
with no change in its kinetic properties (Vmax =19.260.7 and
19.161.7 nmol.mg prot21 for PiT1+/+ and PiT1D5/D5 MEFs,
respectively; Km =124.5638.5 and 134.5617.9 mM for PiT1+/+
and PiT1D5/D5 MEFs, respectively). While real-time RT-PCR
confirmed that PiT1 expression in PiT1D5/D5 MEFs was abolished,
this was associated with a 1.8-fold overexpression of PiT2 mRNA
(Fig. 8C), which could account for the maintenance of normal
Na+-Pi transport in PiT1-null MEFs. Maintenance of a normal Pi
uptake in PiT1-null MEFs supports the idea that the defect in
MEF proliferation was not a consequence of Pi deprivation but
resulted in a transport-independent function of PiT1, consistent
with our recent data obtained in HepG2 and HeLa cells [9].
However, additional in vivo studies are necessary to assign the
observed phenotype to a specific loss of either function of PiT1.
Phenotype of Hypomorphic PiT1neo/neo Mice
Genotyping of litters from PiT1neo/+ intercrosses showed that
PiT1neo/neo pups were present at a lower frequency than expected
(15% vs 25%) reaching only 5% at 2-weeks of age (Table S2),
indicating that a low expression of PiT1 is sufficient to bypass the
embryonic lethality but results in partial postnatal lethality. The
hypomorphic mice that survived were growth retarded (Fig. S3A
to C). At birth, the mean weight of pups was 0.960.1 g for
PiT1neo/neo and 1.560.2 g for wild-type or heterozygotes (Fig. S3A
and B). At 2-3 weeks of age, the difference in weight was maximal
(2-fold lower than controls). The weight of PiT1neo/neo adult mice
ultimately remained approximately 1.3-fold lower than that of
controls. The exact origin of the growth retardation is not known,
but may be related to the anemia and subsequent hypo-
oxygenation of growing tissues, suggested by the pale coloration
of newborn hypomorphic pups (Fig. S3B). Peripheral blood
analysis of 3-week-old mice showed mild but significant erythro-
cyte abnormalities in PiT1neo/neo mice as compared to litter-
matched PiT1+/+ mice (Table S4). The red blood cell counts,
hematocrit, and hemoglobin concentration were significantly
lower in hypomorphic than in wild-type mice. The mild anemia
seen in the mutant was not explained by decreased formation of
erythrocytes, since the reticulocyte number was 2.5-fold higher in
the PiT1neo/neo mice (Table S4), consistent with an absence of
abnormalities in bone marrow smears (data not shown). Together,
these data are rather indicative of hemolytic anemia resulting from
peripheral destruction of erythrocytes. Consistent with this
possibility, PiT1neo/neo mice displayed a significant splenomegaly,
whereas the size of the liver, brain and kidneys were normal (Fig.
S3D). Similarly, peripheral blood smears showed numerous
abnormal red cell morphology, including echinocytes, spherocytes,
and schizocytes (Fig. S3E). The origin of the observed phenotype is
unknown and can arise either from decreased red cell membrane
fluidity or defects in microvascular environment in the PiT1neo/neo
mice. The absence of vessel defect in the PiT1D5/D5 mice argues
against the latter hypothesis, although detailed studies must be
performed. Analysis of lipid membrane composition of mutant and
Figure 8. Disruption of PiT1 in MEFs does not affect Na+-Pi cotransport but leads to reduced proliferation. (A) MEFs proliferation curve.
PiT1D5/D5 MEFs display a mean doubling time of 38 h, whereas PiT1+/+ and PiT1D5/+ MEFs had a growth rate of 18 h and 20 h, respectively. (B) Na+-Pi
uptake in MEFs. Disruption of PiT1 in MEFs does not modify the overall Pi uptake. (C) Quantification of the expression of PiT1 and PiT2mRNAs in PiT1+/+
and PiT1D5/D5 MEFs by real-time RT-PCR. Note the 1.8-fold overexpression of PiT2 mRNA in PiT1-null MEFs. * and # indicate significant differences as
compared to wild-type controls with P,0.05 and P,0.001, respectively (Student’s t test).
doi:10.1371/journal.pone.0009148.g008
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control red blood cells demonstrated significant changes (Table
S5). Monounsaturated fatty acid were increased, whereas poly-
unsatured fatty acid where decreased in PiT1neo/neo mice as
compared to wild-type littermates: mutant red blood cells had
higher levels of 16:1n-7 and 18:1n-9 and lower levels of 18:0 fatty
acids. However, such changes are not known to be associated with
a change in membrane fluidity and may reflect the difference in
the lipid membrane composition between erythrocytes and
reticulocytes [37]. This latter possibility is further supported by
the increase in stearoyl-CoA desaturase index in PiT1neo/neo mice.
More importantly, cholesterol concentration and mean cholester-
ol/phospholipid molar ratio were not different between mutant
and control mice (Table S5), arguing against a striking change in
erythrocytes membrane fluidity. It remains to be determined,
however, whether the decrease of PiT1 per se in the erythrocyte
membrane of PiT1neo/neo mice can account for altered erythrocyte
membrane morphology.
Phenotype of PiT1neo/D5 Compound Heterozygotes
The compound heterozygous PiT1neo/D5 mice express functional
PiT1 levels that are intermediate between the PiT1D5/D5 and
PiT1neo/neo mice (Fig. 1F). Accordingly, several phenotypic features
were found to lie in severity between the null and hypomorphic
PiT1 mice. Embryonic lethality of PiT1neo/D5 mice was found to
arise later in development than for PiT1D5/D5 counterparts,
occurring between E14.5 and E16.5 (Table S3). At E14.5,
PiT1neo/D5 embryos were severely anemic (Fig. S4A). At this stage
mutant livers were hypoplastic, whereas E12.5 mutants and
control livers showed comparable histology (Fig. S4B to E).
Consistent with results obtained in PiT1D5/D5 embryos, no
hemorrhage was found in the PiT1neo/D5 fetuses and no gross
vascular defect could be detected by examination of yolk sacs (Fig.
S4F and G). PiT1neo/D5 circulating nucleated erythrocytes
displayed morphologic features similar to those observed in
controls (Fig. S4H and I) but were 6.9-fold more numerous than
in controls (Fig. S4J). In addition, the level of embryonic
hemoglobin was increased in the compound heterozygotes (Fig.
S4K), suggesting that the relative increase in the number of
nucleated erythrocytes in PiT1neo/D5 is likely to result from the
persistence of primitive yolk sac-derived erythrocytes secondary to
a liver-defect in definitive erythropoiesis production.
Impaired PiT1 Expression in Mice Does Not Affect Early
Skeleton Development
Since PiT1 has been extensively studied in bone and cartilage,
we investigated whether these tissues were affected in PiT1
mutant mice. Alcian blue staining of the initial cartilage matrix
revealed no difference between E12.5 PiT1D5/D5 and PiT1+/+
embryos (Fig. 9A and B), or later in development between E15.5
PiT1neo/D5 and PiT1+/+ embryos (Fig. 9C to H). Alcian blue/
alizarin red S double staining of newborn PiT1neo/neo and wild-
type skeletons showed an impaired mineralization of both long
bones in which endochondral (arising from cartilaginous mold)
ossification takes place, and in the cranial vault and portions of
the upper facial skeleton that develop by intramembranous
ossification without replacing a cartilaginous mold (Fig. 9I to L).
However, these differences were not seen on all of the
hypomorphic newborn pups (data not shown), suggesting that
the impaired mineralization may have been already corrected.
Consistent with this hypothesis, staining of 2-weeks-old skeletons
demonstrated no detectable difference between PiT1neo/neo and
PiT1+/+ mice (Fig. 9M and N). Our data do not exclude an in vivo
role for PiT1 in bone and cartilage biology, but indicate that a
normal expression of PiT1 is not essential for early skeleton
formation during mouse development.
Discussion
In this report we have generated an allelic series of mutant mice
in which PiT1 is expressed from 100% to 0%. Disruption of PiT1
leads to mid-gestation lethality due to severe defects in liver
development, arising from reduced proliferation and massive
apoptosis of liver cells. Impaired liver development causes
dramatic anemia eventually leading to the death of the embryo.
No placental, yolk sac or vascular defects were identified.
Figure 9. Impaired PiT1 expression in mice does not affect early
skeleton development. (A–B) Alcian blue staining of PiT1+/+ and
PiT1D5/D5 E12.5 whole embryos. (C–H) Alcian blue staining of PiT1+/+ and
PiT1neo/D5 E15.5 whole embryos. Higher magnification views (E–H)
demonstrate no difference in skeletal development of the heterozygous
compounds. (I–L) Alcian blue and alizarin red S double staining of one-
day old PiT1+/+ and PiT1neo/neo newborn pups. Note the lack of alizarin
red staining in humerus, verterbraes, cranial vault and upper facial
skeleton (black arrows). (M–N) Alcian blue and alizarin red S double
staining of 15-day old PiT1+/+ and PiT1neo/neo mice. No staining
difference could be evidenced anymore.
doi:10.1371/journal.pone.0009148.g009
PiT1 and Liver Development
PLoS ONE | www.plosone.org 10 February 2010 | Volume 5 | Issue 2 | e9148
Considering the available data on PiT1, our findings are
unexpected. PiT1 is expressed in a wide variety of organs and cell
types and, as a result, the general consensus is that this gene is
ubiquitously expressed. However, this short-cut is misleading and
although its expression is wide, there are large variations in PiT1
expression levels from an organ to another, or under different
physiological conditions [2,7,8]. Moreover, cell-type specific
expression has not been addressed in most tissues except in bone,
which showed that PiT1 is expressed in a subset of hypertrophic
chondrocytes and absent from osteoblasts during mouse develop-
ment [20]. Our results clearly show that the embryo forms,
develops and grows without major defects until E11.5 in the
absence of PiT1, which demonstrates that PiT1 is dispensable for
early development. The over-expression of PiT2 in PiT1-deficient
embryos suggests that PiT2 may compensate for the lack of PiT1
up until this stage. However, decreased proliferation and increased
apoptosis of PiT1-deficient fetal livers arise despite the over-
expression of PiT2 in the liver, demonstrating that PiT2 can not
take over the function of PiT1 in the liver, and argues for distinct
temporal or tissue-specific roles for PiT1 and PiT2. The novel
mouse models described here will be useful tools for future studies
addressing this question in more details.
Liver formation is a crucial checkpoint in fetal hematopoiesis
and development. Livers from E11.5 and E12.5 PiT1D5/D5
embryos were very small, contained hematopoietic precursors
and disorganized islands of hepatocytes. A small liver can be the
result of abnormal hematopoietic cell proliferation, as described in
c-myb-deficient embryos [38], or abnormal erythroid cell prolifer-
ation and differentiation, as seen in Rb2/2 embryos [39,40].
However, we found normal in vitro proliferative and differentiative
function of PiT1D5/D5 hematopoietic committed progenitor cells
making it unlikely that the anemia observed in PiT1D5/D5 embryos
can be attributed to a hematopoietic cell-autonomous defect.
Moreover, although fetal livers are hypoplastic, erythroid
progenitors have the ability to migrate there, arguing against a
fetal liver homing defect. Liver cells from PiT1D5/D5 embryos
underwent a decrease in proliferation and a massive wave of
apoptosis, suggesting that PiT1 provides a proliferation and
survival signal for hepatocytes during a defined stage of liver
morphogenesis. This result was reinforced by the pattern of
expression of PiT1 in the embryo at mid-gestation showing a high
and preferential expression in the liver, and the acute re-
expression of PiT1 following partial hepatectomy in adult liver,
consistent with a crucial role of PiT1 in liver growth. The
molecular mechanisms by which PiT1 mediates a pro-proliferative
and anti-apoptotic function in the developing liver have yet to be
clarified. In PiT1-null mice, the liver bud forms and the following
proliferation period needed of expansion of the liver is highly
affected. This phenotype is somewhat reminiscent of mice lacking
RelA [41], Raf-1 [42,43], MKK4 [44], ATF2 [45], MKK7 [46] or
c-Jun [47]. There is no data in the literature linking PiT1 to
signaling pathways and our attempts to detect changes in the
phosphorylation of relevant signaling pathways in the liver were
unsuccessful (data not shown). As the mammalian target of
rapamycin (mTOR) is a kinase that integrates signals from
nutrients and growth factors to regulate cell growth and cell cycle
progression coordinately, we also investigated the phosphorylation
state of S6K1, S6, Akt1 and 4EBP1 proteins but could not show
defects in PiT1-deficient MEFs (data not shown). We have shown
that the proliferation rate of PiT1-null MEFs is decreased while the
Na+-Pi transport activity remains unchanged, most probably due
to the over-expression of PiT2 that is observed in PiT1-deficient
MEFs. This result is consistent with our recent data identifying a
novel function of PiT1, not shared by PiT2, that is related to cell
proliferation, and is independent of its Na+-Pi transport activity
[9]. In PiT1-null fetal livers we show that PiT2 is overexpressed
but that this overexpression does not compensate for the loss of
PiT1. Therefore it is tempting to speculate that as in MEFs,
HepG2 and HeLa cells [9], a PiT2 overexpression in mutant livers
could compensate for a loss of Na+-Pi transport activity (as it is
shared by PiT1 and PiT2), but not for a loss of a PiT1-specific
function such as the proliferation-related function of PiT1.
However, this remains an hypothesis since the generation of new
animal models carrying mutations of either function of PiT1
(proliferation- or transport-related) is necessary to determine
whether the observed phenotype of PiT1-null mice is due to a
loss of either or both function of PiT1.
To date, most studies conducted on PiT1 have focused on the
expression and Na+-Pi transport activity of PiT1 in tissues in which
Pi biology plays an important role, mainly bone and vascular
physiology. However, recent observations may be related to a
transport-independent function of PiT1. Studies conducted in
VSMCs have led to the proposal that an increase in Pi influx
through the plasma membrane could lead to the to the
transdifferentiation of VSMCs in osteoblast-like cells and calcifi-
cation of the extracellular matrix under high extracellular Pi
concentration [19]. Although PiT1 was irrefutably shown to be
involved in this process, the mechanisms underlying the action of
PiT1 is now being debated [48]. Notably, a recent report shows
that under physiological conditions, the Pi-transport activity of
PiT1 is saturated [49], implying that only an increase in the
capacity (i.e. enhanced expression of functional Pi transporters)
can mediate an increase in Pi influx. However, not only such an
increase has not been evidenced but the expression of PiT1 in
VSMCs is very low, making unlikely that PiT1 mediates its effect
on vascular calficification through its Na+-Pi cotransport activity
[48,50]. While we were writing this paper, a technical report
describing the generation of null and floxed alleles of PiT1 has
been published [51]. The authors have deleted exon 3 and 4 of
PiT1 which also led to embryonic lethality at mid-gestation around
E12.5, although with a lower penetrance than in our model which
may be due to differences in the genetic background used.
Similarly to our results, they reported that PiT1-null embryos were
anemic, although the origin of the anemia was not investigated
and was based only on external observation. Of note, the authors
reported possible defects in supercifial vasculature of yolk sac
based on visual external observation [51]. However, although we
also found that mutant yolk sacs appear white, we used specific
endothelial cell immunostaining to show that there were no major
vascular defects shortly before the occurrence of embryonic death
at E12.5. In summary, although PiT1 does not seem to be essential
to the development of a normal vasculature, it remains to be
determined whether PiT1 is instrumental to a Pi-induced vascular
calcification in vivo through the generation of animals carrying a
tissue-specific deletion of PiT1.
The regulation of PiT1 has been well documented in bone and
cartilage models, due to the requirement of large amounts of Pi in
bone physiology. PiT1, but not PiT2, mRNA and Na+-Pi transport
were found to be regulated in osteoblast-like and chondrogenic
cells by various factors, mainly Pi, IGF-1, BMP2 and TGF-b
[10,12,13,14,16,17]. Moreover, PiT1, but not PiT2 is upregulated
during osteoblast differentiation [15]. However, all these studies
have been conducted in vitro, and it is still not clear whether the
Na+-Pi transport function of PiT1 is implicated in these processes
in normal physiological conditions. The weak expression of PiT1
in bone, particularly in osteoblasts, its discrete expression in a
subset of hypertrophic chondrocytes late in development [20],
together with its low transport capacity [22] make it an unlikely
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candidate to face the tremendous Pi needs for bone and cartilage
mineralization. The main role of PiT1 in bone may rather be to
mediate extracellular signals, as was recently proposed [52],
independently, or additionally, of its transport function. Never-
theless, our data clearly show that there is no developmental
defects in both vascular and cartilage compartments of PiT1-
depleted mice. Although our results in hypomorphic PiT1 mice
show that, at birth, the mineralization of bone was delayed, its
rapid normalization argues against a major predominant role for
PiT1 in skeleton mineralization. The availability of PiT1lox/lox mice
will help at elucidating this particular point using appropriate Cre-
expressing mice for generating bone and cartilage-specific deletion
of PiT1.
In summary, through the establishment of a PiT1 mutant allelic
series we have uncovered a specific role of PiT1 in normal liver
growth. We have shown that PiT1 is essential to embryonic
development, and is non redundant as PiT2 could not compensate
for the loss of PiT1. On the other hand, PiT1 seems not to be
essential for skeleton and vasculature development. Although this
study opens new avenues on the functions of the PiT protein
family, the molecular mechanisms leading to the impairment of
liver development remain to be elucidated, including open
questions of whether the proliferation-associated function of
PiT1 and/or the Na+Pi transport activity of PiT1 and PiT2 are
involved in the observed phenotypes.
Supporting Information
Figure S1 Aberrant splicing of the PiT1neo allele. (A) Schematic
representation of the PiT1neo and PiT1D 5 alleles, with black boxes
representing PiT1 coding sequences. The neo cassette and loxP sites
are also depicted. Below the allele are diagrams representing the
corresponding mRNAs produced by these alleles, as determined
by the RT-PCR analysis shown in B using the primers indicated
(arrow heads). (B) RNA isolated from the progeny of PiT1neo/+ or
PiT1D 5/+ mice was reverse transcribed, and assayed by PCR using
the primers indicated. Sequence analysis of these PCR products
revealed the aberrant splicing of the PiT1neo allele, as illustrated in
the diagram in A. The detection of similar size amplification
products in samples derived from wild-type and PiT1neo/neo when
primer pair F1R3 was used indicates that some wild-type PiT1
mRNA is produced by the PiT1neo allele.
Found at: doi:10.1371/journal.pone.0009148.s001 (0.31 MB TIF)
Figure S2 Absence of placental defect in PiT1D 5/D 5 embryos. (A)
External appearance of PiT1+/+ (left) and PiT1D 5/D 5 (right) placentas
at E12.5. (B–C) Haematoxilin and eosin (H&E)-stained placental
sections at E12.5. The size and histological appearance of the
different layers are comparable between the wild-type and the
mutant. Note the presence of less red blood cells in the mutant than in
the wild-type. (D–E) Anti-PECAM-1 IHC of PiT1+/+ and PiT1D 5/D 5
placental sections at E12.5 illustrating the presence of endothelial cells
in both genotypes. (F–G) Ki67 staining of placental sections from
PiT1+/+ and PiT1D 5/D 5 mice. Most cells were positively labelled
(white arrow), and few were negative (black arrow), demonstrating
active and comparable cycling in both genotypes. (H–I) TUNEL
analysis on placental sections from PiT1+/+ and PiT1D 5/D 5 mice
demonstrate a low and comparable level of apoptotic cells (white
arrow) in both genotypes. Sections were stained with DAPI to
visualize the nuclei (blue). La: labyrinth; St: spongiotrophoblast; Gc:
giant cells; Md: maternal decidua. Bars, 1 mm (A), 100 mm (B–I).
Found at: doi:10.1371/journal.pone.0009148.s002 (7.39 MB TIF)
Figure S3 Phenotype of PiT1neo/neo mice. (A) Body weight as a
function of age. Each point represents mean 6 SD from 3 to 10
measurements. (B) Gross morphological appearance of PiT1+/+ and
PiT1neo/neo mice at birth. Note the smaller size and paler coloration
of the mutant. (C) Gross appearance of PiT1+/+ and PiT1neo/neo mice
at 15-days of age. (D) Organ weight relative to body weight at
15-days of age. The spleen of the hypomorphic PiT1 mouse is
2.4-fold larger than its wild-type counterpart. ** indicates signi-
ficant differences as compared to wild-type controls with P,0.01
(Student’s t test). (E) Peripheral blood smears from 3-weeks old
PiT1+/+ and PiT1neo/neo littermates. Numerous red cells with
abnormal morphology are present, including echinocytes (black
arrows), spherocytes (white arrows), and schizocytes (grey arrows).
Found at: doi:10.1371/journal.pone.0009148.s003 (2.82 MB TIF)
Figure S4 Phenotype of PiT1neo/D 5 compound heterozygotes.
(A) Morphological appearance of PiT1neo/D 5 E14.5 embryos
(right), as compared to wild-type littermates (left). Note the severe
anemia and slight decrease in size. (B–C) H&E staining of E14.5
sagital sections from PiT1+/+ and PiT1neo/D 5 livers. The mutant
liver shows desorganized parenchyme, reduced cellularity and
pyknotic nuclei (white arrow). (D–E) H&E staining of E12.5
sections from PiT1+/+ and PiT1neo/D 5 livers showing no difference
between the two genotypes. Bar, 100 mm. (F–G) Close examina-
tion of yolk sac membranes from wild-type and PiT1neo/D 5 E14.5
embryos demonstrate the presence of a highly developed
vasculature (black arrows) characterized by a decrease in red
blood cell number. (H–I) May-Gru¨nwald/Giemsa staining of
peripheral blood smears from E14.5 PiT1+/+ and PiT1neo/D 5
littermates. Note the similar morphology of red blood cells, but the
higher percentage of nucleated erythrocytes (black arrows). (J)
Quantification of the nucleated erythrocytes in the peripheral
blood of E15.5 PiT1+/+ and PiT1neo/D 5 littermates. (K) RT-PCR
analysis of the expression of globin chains in E15.5 PiT1+/+ and
PiT1neo/D 5 littermate livers, and expressed as a ratio between fetal
and adult expression. * and # indicate significant differences as
compared to wild-type controls with P,0.05 and P,0.001,
respectively (Student’s t test).
Found at: doi:10.1371/journal.pone.0009148.s004 (5.62 MB TIF)
Table S1 Primers used in this study.
Found at: doi:10.1371/journal.pone.0009148.s005 (0.09 MB
DOC)
Table S2 Genotypes of the progeny obtained by crossing
heterozygous PiT1neo/+ mice. a Surviving embryos were defined
as those with beating hearts. *, *** significant differences between
observed frequency of living PiT1neo/neo and expected frequency of
25%, according to Mendelian distribution of the genotypes, with
P,0.05 and P,0.001, respectively. Significance of distribution
was calculated using x2 test.
Found at: doi:10.1371/journal.pone.0009148.s006 (0.05 MB
DOC)
Table S3 Genotypes of the progeny resulting from PiTneo/+ and
PiTD 5/+intercrosses. a Expected frequency according to Mende-
lian distribution of genotypes is 25% for each genotype. No
surviving PiT1neo/D 5 embryos were found alive past E16.5 stage.
b Surviving embryos were defined as those with beating hearts.
*, ** and *** significant differences between observed frequency
of living PiT1neo/D 5 and expected frequency of 25%, according
to Mendelian distribution of the genotypes with P,0.05, P,0.01
and P,0.001, respectively. Significance of distribution was
calculated using x2 test.
Found at: doi:10.1371/journal.pone.0009148.s007 (0.05 MB
DOC)
Table S4 Hematologic variables in adult mice, according to
genotype. Circulating blood of 3-week-old PiT1+/+, PiT1neo/+ and
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PiT1neo/neo mice mice was analyzed on a Vet’ABC counter (SCIL,
Viernheim, Germany). Reticulocyte count was determined on
blood smears using a reticulocyte stain (Sigma). The data shown
were obtained from a litter-matched group of mice (n = 3–4) and
are representative of three experiments with independent groups
of animals. Values are means 6 SD. * and ** indicate significant
differences between PiT1neo/neo and wild-type controls with P,0.05
and P,0.01, respectively (Student’s t test). There was no
significant difference between PiT1+/+ and PiT1neo/+ adults in
any assay.
Found at: doi:10.1371/journal.pone.0009148.s008 (0.06 MB
DOC)
Table S5 Fatty acid, phospholipids and cholesterol profiles of
PiT1+/+, PiT1neo/+ and PiT1neo/neo erythrocyte membranes. a values
are given as the mean from three mice in each group 6 SD. The
fatty acid contents are expressed as molar percentages. Percent-
ages were significantly different from control by the two-tailed t-
test with *P,0.05 and **P,0.01. b Unsaturation expressed as
double bond index (calculated as the sum of each unsaturated fatty
acid concentration multiplied by its double bond number and
divided by the total unsaturated fatty acid concentration). SCD:
stearoyl-CoA desaturase index (de novo synthesis of 18:1n-9 from
18:0); MUFA: monounsaturated; PUFA: polyunsaturated; EFA:
essential. c values are given as the mean from three mice in each
group 6 SD. PE: phosphatidylethanolamine; PI: phosphatidyli-
nositol; PS: phosphatidylserine; PC: phosphatidylcholine; SM:
sphingomyelin; acidic: PI+PS; neutral: PE+PC+SM; PE+PS+PI:
preferentially internal layer phospholipids; PC+SM: preferentially
external layer phospholipids; PL: phospholipids.
Found at: doi:10.1371/journal.pone.0009148.s009 (0.10 MB
DOC)
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